• PPM-18 and the NF-κB–iNOS Evidence Gap

  2026-10-08

  PPM-18 is a chemically synthesized naphthoquinone derivative used to investigate NF-κB-regulated iNOS expression. This article distinguishes supplier-reported activity from peer-reviewed evidence and explains what an oridonin bone-remodeling study can—and cannot—tell us about inflammation, immune response modulation, and sepsis research.

• PPM-18, NF-κB and iNOS: Research Context

  2026-10-08

  A source-grounded overview of PPM-18 and N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide, emphasizing reported NF-κB–iNOS findings, conceptual applications in inflammation and sepsis research, comparison with a peer-reviewed oridonin bone-remodeling study, and key evidence limitations.

• PTT and CD47 Blockade in Oral Cancer

  2026-10-07

  A 2026 study shows that photothermal therapy can strengthen CD47 blockade in oral squamous cell carcinoma by pairing a macrophage-activating eat-me signal with extracellular-matrix remodeling that improves tumor access. The preclinical findings support a dual-barrier model of treatment synergy, while leaving questions about clinical translation, mechanism-specific causality, and treatment safety.

• Irinotecan: Connecting Tumor Killing to Liver Toxicity

  2026-10-07

  Irinotecan research is increasingly understood through two linked phenotypes: tumor DNA damage and chemotherapy-associated gut–liver injury. This evidence-centered analysis connects CPT-11 pharmacology with intestinal barrier dysfunction, LPS signaling, and neutrophil extracellular traps while defining the limits of preclinical interpretation.

• Sunitinib in RTK and Tumor Angiogenesis Research

  2026-10-06

  A source-grounded overview of Sunitinib as a multi-targeted receptor tyrosine kinase inhibitor, its conceptual use in angiogenesis and cancer-model research, and the limits of connecting oncology pharmacology with recent Zika virus phosphoproteomics findings.

• Sulfo-Cy3 NHS Ester: Evidence, Scope and Limits

  2026-10-06

  A source-grounded overview of Sulfo-Cy3 NHS Ester, the principles behind amine-reactive fluorescent labeling, and what a recent collateral-circulation study does—and does not—show about interpreting fluorescence in vascular biology.

• Chloroquine in Cancer Therapy: Review Findings

  2026-10-05

  The 2024 review by Liu and colleagues examines how Chloroquine may influence cancer biology through both autophagy-dependent and autophagy-independent mechanisms. Its main contribution is a broad pharmacological synthesis linking lysosomal effects, cell-death pathways, combination therapy, toxicity, and translational limitations rather than treating autophagy inhibition as a complete explanation.

• Chloroquine Diphosphate in Cancer Research: Evidence

  2026-10-05

  This source-grounded overview examines Chloroquine Diphosphate as an autophagy and endosomal-pathway research tool, while separating supplier claims from peer-reviewed findings. It places the compound alongside a 2023 colorectal cancer study involving 3-bromopyruvate and cetuximab, explains possible conceptual applications in autophagy assay design and treatment-response research, and defines the evidence boundaries that prevent conclusions about chloroquine-specific cancer efficacy.

• AMPK–p62 Feedback Under Metabolic Stress

  2026-10-04

  Choi and colleagues identify a double-positive feedback loop linking AMPK and SQSTM1/p62 during metabolic stress, allowing coordinated activation of AMPK-dependent energy adaptation and NFE2L2/NRF2 antioxidant defense. The study connects lysosomal stress, KEAP1 degradation, TFEB/TFE3 regulation, and TAK1 signaling, while also defining important boundaries around the effects of lactic-acid-associated proton availability.

• WZ4003: NUAK1/2 Inhibitor Evidence Guide

  2026-10-03

  WZ4003 is a NUAK1/2 inhibitor with reported nanomolar biochemical potency and cellular evidence of NUAK pathway engagement. Peer-reviewed ex vivo brain-slice data link NUAK inhibition with lower tau Ser356 phosphorylation, while model-specific limitations prevent direct claims of therapeutic efficacy.

• TCF25 Links Lysosomal Acidification to Cell Death

  2026-10-01

  Ren et al. identify TCF25 as a nutrient-responsive regulator that strengthens V-ATPase-dependent lysosomal acidification during glucose starvation. The study shows that this response initially supports autophagy and ATP production but, during prolonged starvation, drives ferritinophagy, lysosomal membrane permeability, and lysosome-dependent cell death, with implications for hepatic ischemia-reperfusion injury.

• Triamcinolone: In Vitro Workflow and QC Guide

  2026-10-01

  Triamcinolone (B1859) provides a defined synthetic glucocorticoid agonist for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solubility, stock preparation, storage, and assay controls; the research compound is not intended for diagnostic, therapeutic, or clinical use.

• CCK-8 Restores Morphine-Impaired Hippocampal LTP

  2026-09-30

  The reference study showed that intracerebroventricular CCK-8 restored hippocampal long-term potentiation weakened by acute morphine exposure in rats. Pharmacological blockade identified CCK2, rather than CCK1, receptors as the principal mediators, providing a mechanistic link between brain–gut peptide signaling, synaptic plasticity, and morphine-associated memory impairment.

• Oligo (dT) 25 Beads: mRNA Purification Guide

  2026-09-30

  Oligo (dT) 25 Beads provide a magnetic workflow for capturing polyadenylated eukaryotic mRNA from total RNA or animal and plant samples. They are not a universal RNA purification reagent and should not be used as the sole strategy for non-polyadenylated RNA, small RNA, or bacterial transcriptome recovery.

• Senolytic Targeting After Temozolomide in Glioblastoma

  2026-09-29

  The reference study shows that temozolomide-treated glioblastoma cells can persist in a senescent, apoptosis-resistant state supported by c-IAP2 and Bcl-2. Pharmacological inhibition with BV6 and venetoclax selectively increased death in these residual cells, providing a rationale for combining DNA-damaging therapy with senolytic strategies while highlighting important limits of cell-line evidence.

8641 records 1/577 page Next 12345 下5页 Last page